Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Understanding ISO 11137-2:2016 — Sterilization of Health Care Products: Establishing the Sterilization Dose
A Comprehensive Guide to Radiation Sterilization Dose Establishment Methods and Compliance under CAN/CSA-ISO 11137-2:16
Scope and Overview
ISO 11137-2:2016, adopted in Canada as CAN/CSA-ISO 11137-2:16 (commonly referred to as ISO 11137-2-16), is the second part of the ISO 11137 series dedicated to the sterilization of health care products by ionizing radiation (gamma, electron beam, and X‑ray). This standard provides the detailed methodology for establishing the sterilization dose—the minimum absorbed dose necessary to achieve a prescribed sterility assurance level (SAL)—and for maintaining the validated dose through periodic audits.
Part 2 is used in conjunction with ISO 11137-1 (general requirements) and ISO 11137-3 (dosimetry aspects). It applies to health care products (medical devices, pharmaceutical packaging, etc.) that are terminally sterilized by radiation. The standard does not cover aseptic processing or non‑radiation sterilization modalities.
Tip: CAN/CSA-ISO 11137-2:16 is identical to the international version ISO 11137-2:2016. Manufacturers seeking a single-step certification for the Canadian market can reference the CSA adoption while maintaining global harmonization.
Technical Requirements of ISO 11137-2:2016
The core objective of ISO 11137-2 is to define scientifically valid procedures for determining a sterilization dose that delivers an SAL of 10−6 (or other specified SAL) with a high degree of confidence. Three principal methods are described:
Method 1: Bioburden-Based Dose Establishment
This method utilizes the product’s bioburden data (number and radiation resistance of the natural microbial population). The sterilization dose is derived from a series of incremental dose‑response experiments carried out on product units or on a sub‑process portion (SIP). The method requires knowledge of both the average bioburden and its resistance distribution. It is particularly suitable for products that have a low to moderate bioburden and for which a large body of historical data exists.
Method 2: Incremental Dose to SAL 10−2 and Extrapolation
Method 2 is an empirical approach in which the dose needed to reduce the microbial population to an SAL of 10−2 is determined experimentally. This dose is then extrapolated to the target SAL (e.g., 10−6) using a scaling factor derived from the slope of the survivor curve. This method is useful when the bioburden resistance is high or when limited bioburden data are available.
VDmax Methods (VDmax25 and VDmax15)
The VDmax methods are abbreviated dose‑establishment procedures that do not require determination of the resistance distribution. They use a verification dose experiment at 25 kGy or 15 kGy, respectively, combined with a maximum allowable bioburden to confirm that a sterilization dose of 25 kGy (or 15 kGy) achieves an SAL of 10−6. The VDmax methods are favored for routine validation because they are simpler and less costly, but they are only applicable when the product bioburden is below a specified limit (typically ≤ 1000 CFU for VDmax25).
Verification Dose Experiments and SIP Concepts
Verification dose experiments are a cornerstone of ISO 11137-2. They test the hypothesis that the established sterilization dose will, in routine processing, deliver the required SAL. The verification dose is typically 60–80% of the estimated sterilization dose and is applied to a sample of the product. If the number of positive sterility tests does not exceed a predefined value (often 0 positives out of 100 units for an audit), the sterilization dose is considered verified. The use of a Sub‑Process Portion (SIP) is allowed when the product is too large or complex to test as a whole; the SIP data can be scaled to the full product via established extrapolation rules.
Important: When using a SIP, the manufacturer must ensure that the SIP is representative of the full product in terms of bioburden and radiation resistance. Inappropriate SIP selection can lead to under‑ or over‑estimation of the required dose.
| Method | Basis | Bioburden Limit | Bioburden Resistance Required? | Typical SAL | Suitable for Complex Products |
|---|---|---|---|---|---|
| Method 1 | Bioburden & resistance | None (but high bioburden increases testing) | Yes | 10−6 | Flexible |
| Method 2 | Incremental dose to SAL 10−2 | No fixed limit | No | 10−6 | Yes |
| VDmax25 | Verification dose at 25 kGy | ≤ 1000 CFU per product or SIP | No | 10−6 | Limited (pre‑filtered) |
| VDmax15 | Verification dose at 15 kGy | ≤ 10 CFU per product or SIP | No | 10−6 | Very limited |
Implementation Highlights
Successfully applying ISO 11137-2 requires careful planning and integration with other quality management processes. Key implementation steps include:
- Product Family Grouping: Products with similar bioburden profiles and radiation response can be grouped to reduce the number of validation runs. The standard provides criteria for product family establishment (e.g., similar materials, manufacturing processes, and bioburden levels).
- Bioburden Determination: Bioburden must be measured in accordance with ISO 11737-1. Over 10–20 product units are typically sampled to obtain a reliable estimate of both the mean bioburden and the confidence limits.
- Verification Dose Audit: A sterilization dose audit must be performed at least annually and whenever significant changes occur in product design, raw materials, or manufacturing environment. The audit re‑verifies that the currently used sterilization dose remains adequate.
- Dose Mapping: While not covered explicitly in Part 2, the sterilization dose must be delivered uniformly to the product. Routine dose mapping per ISO 11137-3 and ISO 11137-1 is essential to confirm that the established dose is uniformly achievable in the irradiator.
Best Practice: Maintain a detailed validation file that includes all bioburden data, verification dose results, SIP justification (if used), and audit records. This documentation is critical for regulatory submissions and for demonstrating ongoing compliance during audits.
Compliance and Certification Notes
Manufacturers who adopt CAN/CSA-ISO 11137-2:16 can claim compliance with both the ISO standard and the Canadian requirements. Key compliance points to keep in mind:
- Regulatory Acceptance: CAN/CSA-ISO 11137-2:16 is recognized by Health Canada and is often accepted by other regulators (e.g., FDA, EU Notified Bodies) when the manufacturer declares conformity to the ISO version.
- Transition from Earlier Editions: The 2016 edition replaced ISO 11137-2:2013 and introduced clarifications on SIP handling and VDmax applicability. Manufacturers should review their current validation documentation to ensure alignment with the latest requirements.
- Audit Evidence: Certification bodies will expect to see evidence that the chosen dose‑establishment method is correctly applied, verification dose experiments are performed on a regular basis (at least yearly), and any deviation is documented and justified.
- Combination Standards: For a complete radiation sterilization management system, the standard should be used together with ISO 11137-1 (requirements for validation and routine control) and ISO 11137-3 (dosimetry). Many certifying bodies require all three parts to be audited together.
Common Pitfall: Relying on a single batch of product for bioburden determination can yield a low estimate, leading to a falsely reduced sterilization dose. Always use multiple production lots (preferably over a period of time) to capture natural variation and avoid non‑compliance.
In summary, ISO 11137-2:2016 (CAN/CSA-ISO 11137-2:16) provides a robust technical framework for establishing a sterilization dose that ensures product safety and regulatory consistency. By understanding the strengths and limitations of each method—Method 1, Method 2, and VDmax—manufacturers can select the most appropriate and cost‑effective approach while maintaining the highest levels of sterility assurance.
Q: What is the difference between ISO 11137-2 and ISO 11137-1?
A: ISO 11137-1 covers the general requirements for validation and routine control of radiation sterilization (e.g., quality system, dose mapping, process definition). ISO 11137-2 specifically provides the test methods and statistical procedures used to establish the sterilization dose for a product.
A: ISO 11137-1 covers the general requirements for validation and routine control of radiation sterilization (e.g., quality system, dose mapping, process definition). ISO 11137-2 specifically provides the test methods and statistical procedures used to establish the sterilization dose for a product.
Q: When should I use the VDmax method instead of Method 1 or Method 2?
A: VDmax methods are preferred when the product bioburden is low and stable (e.g., ≤ 1000 CFU for VDmax25 and ≤ 10 CFU for VDmax15). They reduce the number of sterility tests and the overall validation effort. However, if bioburden resistance is high or product bioburden exceeds the VDmax limits, either Method 1 or Method 2 must be used.
A: VDmax methods are preferred when the product bioburden is low and stable (e.g., ≤ 1000 CFU for VDmax25 and ≤ 10 CFU for VDmax15). They reduce the number of sterility tests and the overall validation effort. However, if bioburden resistance is high or product bioburden exceeds the VDmax limits, either Method 1 or Method 2 must be used.
Q: How often do I need to perform a sterilization dose audit?
A: The standard requires a sterilization dose audit at least every 12 months. In addition, an audit must be performed whenever there are significant changes in the product, packaging, sterilization process, or manufacturing environment that could affect the product bioburden or radiation resistance.
A: The standard requires a sterilization dose audit at least every 12 months. In addition, an audit must be performed whenever there are significant changes in the product, packaging, sterilization process, or manufacturing environment that could affect the product bioburden or radiation resistance.
Q: Is CAN/CSA-ISO 11137-2:16 identical to the international standard?
A: Yes, the Canadian adoption is identical to ISO 11137-2:2016. There are no national modifications. However, manufacturers exporting to Canada should ensure they reference the CSA designation (CAN/CSA-ISO 11137-2:16) on their documentation when required by Health Canada.
A: Yes, the Canadian adoption is identical to ISO 11137-2:2016. There are no national modifications. However, manufacturers exporting to Canada should ensure they reference the CSA designation (CAN/CSA-ISO 11137-2:16) on their documentation when required by Health Canada.
© 2026 Technical Insight Series. This article is for informational and educational purposes only. Consult the official standards documents for full compliance requirements.